Xiao-xia R. Niu

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Letter: Defining the Incremental Predictive Value of HBsAg in Hepatocellular Carcinoma Risk Prediction, Authors' Reply.

Letter: Defining the Incremental Predictive Value of HBsAg in Hepatocellular Carcinoma Risk Prediction, Authors' Reply.

Journal: Alimentary pharmacology & therapeutics

Published: July 30, 2026

The impact of blood ammonia after interventional therapy on the prognosis of patients with unresectable hepatocellular carcinoma.

The impact of blood ammonia after interventional therapy on the prognosis of patients with unresectable hepatocellular carcinoma.

Journal: iLIVER

Published: March 05, 2026

HBsAg Quantification-Based Models for Predicting Hepatocellular Carcinoma Risk in Nucleos(t)ide Analogs-Experienced Patients With Chronic Hepatitis B: The HBsAg-HCC Score.

HBsAg Quantification-Based Models for Predicting Hepatocellular Carcinoma Risk in Nucleos(t)ide Analogs-Experienced Patients With Chronic Hepatitis B: The HBsAg-HCC Score.

Journal: Alimentary pharmacology & therapeutics

Published: January 28, 2026

Assessment of significant hepatic damage in young patients with chronic hepatitis B to initiate the antiviral treatment: The APLB score.

Assessment of significant hepatic damage in young patients with chronic hepatitis B to initiate the antiviral treatment: The APLB score.

Journal: Antiviral research

Published: April 18, 2025

Leveraging the gut microbiome to understand the risk factor of cognitive impairment in patients with liver cirrhosis.

Leveraging the gut microbiome to understand the risk factor of cognitive impairment in patients with liver cirrhosis.

Journal: European journal of gastroenterology & hepatology

Published: February 20, 2025

Metabolic syndrome is associated with significant hepatic fibrosis and steatosis in patients with nonalcoholic steatohepatitis.

Metabolic syndrome is associated with significant hepatic fibrosis and steatosis in patients with nonalcoholic steatohepatitis.

Journal: iLIVER

Published: December 28, 2023

Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury.

Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury.

Journal: Frontiers in pharmacology

Published: October 16, 2022

Reply.

Reply.

Journal: Hepatology (Baltimore, Md.)

Published: January 28, 2022

Reply.

Reply.

Journal: Hepatology (Baltimore, Md.)

Published: January 25, 2022

The LAC Score Indicates Significant Fibrosis in Patients With Chronic Drug-Induced Liver Injury: A Large Biopsy-Based Study.

The LAC Score Indicates Significant Fibrosis in Patients With Chronic Drug-Induced Liver Injury: A Large Biopsy-Based Study.

Journal: Frontiers in pharmacology

Published: June 30, 2021

Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study.

Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study.

Journal: Metabolism open

Published: March 10, 2021

Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.

Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: July 28, 2020

Showing 1-12 of 17

Last Updated: 09/26/2026